The phrase "a decline in bone" is correct and usable in written English.
It can be used in contexts discussing health, medical conditions, or research related to bone density or strength.
Example: "The study revealed a significant decline in bone density among older adults."
Alternatives: "a decrease in bone" or "a reduction in bone".
Poor bone marrow is also associated with a decline in bone architectural quality.
Metabolic bone diseases such as osteoporosis usually cause a decrease in bone mass and a deterioration of bone microarchitecture leading to a decline in bone strength.
The disorders of bone remodeling are accompanied by an increase in marrow fat and a decline in bone mass [ 5].
20 Long-term hospitalisation leads to lack of exercise, which is a factor that may cause a decline in bone density.
A rise in gastrointestinal (GI) adverse events (AEs) and a decline in bone mineral density (BMD) was observed in patients previously tolerant to brand alendronate shortly after generic versions were introduced in July 2005 to the Canadian market.
With age in humans, there is a decline in bone mass and architecture to the extent that bones become sufficiently fragile that low levels of trauma can lead to fracture [4].
The purpose of modeling and remodeling during adulthood is simply to maintain bone strength by damage repair but four age-related changes compromise bone's material composition and structure; a decline in periosteal bone formation, a decline in the volume of bone formed by each basic multicellular unit (BMU), continued resorption by each BMU, and high remodeling.
Medullary and cortical bone are both resorbed in response to egg-laying, but since medullary bone is remodeled at a much higher rate than cortical bone there is a decline in cortical bone mass during the productive period [ 9].
Human aging is associated with a progressive decline in bone mass and an accumulation of marrow fat, suggesting that osteogenesis defect might be the reason.
Treatment related menopause can lead to a rapid decline in bone density, and there may be a future role for the use of bisphosphonates in the adjuvant setting to both maintain bone health and prevent breast cancer recurrence.
(Women are especially vulnerable, because estrogen loss at menopause can cause a precipitous decline in bone density).
